Alpha 2.0
Login Register
» Articles » PMID: 36204172

Psychiatric Uses of Gabapentin

Overview
Journal Innov Clin Neurosci
Date 2022 Oct 7
PMID 36204172
Authors
Jon C Martin
Danielle Gainer
Affiliations
Soon will be listed here.
Abstract

Objective: This article reviews evidence-based psychiatric uses of gabapentin, along with associated risks.

Method Of Research: An extensive literature review was conducted, primarily of articles searchable in PubMed, relating to psychiatric uses, safety, and adverse effects of gabapentin.

Results: Evidence supports gabapentin as a treatment for alcohol withdrawal and alcohol use disorder. There is sufficient evidence to consider gabapentin as a third-line treatment for social anxiety disorder and severe panic disorder. Evidence does not support the use of gabapentin for bipolar disorder, major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), stimulant use disorder, or opioid withdrawal. Risks of gabapentin use are highest among those with a history of a substance use disorder and those concurrently taking opioids.

Conclusion: While gabapentin has a place in psychiatry for a select few indications, the literature does not support its use for many studied diagnoses.

Citing Articles

Molecular Mechanisms and Therapeutic Potential of Gabapentin with a Focus on Topical Formulations to Treat Ocular Surface Diseases.

Rusciano D Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794193 PMC: 11124268. DOI: 10.3390/ph17050623.

Prediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder using electronic medical records by deep learning models.

Miranda O, Fan P, Qi X, Wang H, Brannock M, Kosten T Drug Alcohol Depend. 2024; 255:111066.

PMID: 38217979 PMC: 10853953. DOI: 10.1016/j.drugalcdep.2023.111066.

Prediction of Adverse Events Risk in Patients with Comorbid Post- Traumatic Stress Disorder and Alcohol Use Disorder Using Electronic Medical Records by Deep Learning Models.

Miranda O, Fan P, Qi X, Wang H, Brannock M, Kosten T Res Sq. 2023; .

PMID: 37790550 PMC: 10543461. DOI: 10.21203/rs.3.rs-3299369/v1.

Effect of Gabapentin-Fluoxetine Derivative GBP1F in a Murine Model of Depression, Anxiety and Cognition.

Gohar A, Ali G, Rashid U, Rauf K, Arif M, Khan M Drug Des Devel Ther. 2023; 17:1793-1803.

PMID: 37346999 PMC: 10281524. DOI: 10.2147/DDDT.S407229.

References
1.
Furieri F, Nakamura-Palacios E . Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007; 68(11):1691-700. DOI: 10.4088/jcp.v68n1108. View
2.
Salehi M, Kheirabadi G, Maracy M, Ranjkesh M . Importance of gabapentin dose in treatment of opioid withdrawal. J Clin Psychopharmacol. 2011; 31(5):593-6. DOI: 10.1097/JCP.0b013e31822bb378. View
3.
Peckham A, Fairman K, Sclar D . All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population. Drug Saf. 2017; 41(2):213-228. DOI: 10.1007/s40264-017-0595-1. View
4.
Stein M, Kerridge C, Dimsdale J, Hoyt D . Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress. 2007; 20(6):923-32. DOI: 10.1002/jts.20270. View
5.
Ling W, Shoptaw S, Hillhouse M, Bholat M, Charuvastra C, Heinzerling K . Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence. Addiction. 2011; 107(2):361-9. PMC: 4122522. DOI: 10.1111/j.1360-0443.2011.03619.x. View